Low molecular weight heparins - should prophylactic doses be used in patients with renal impairment?

This updated Medicines Q & A reviews the evidence available and considers when prophylactic doses of low molecular weight heparins can be used in patients…

What is the evidence for the use of Low Molecular Weight Heparins for the prophylaxis of travel-related thrombosis?

This Medicines Q&A evaluates the evidence for using low molecular weight heparins for the prevention of travel-related venous thromboembolism

Shortage of Clexane: alternative treatment options

In light of current shortage of Clexane, a table of licensed low molecular weight heparins and fondaparinux has been drawn up to compare/contrast key prescribing parameters and…

Safety in Lactation: Drugs for thromboembolic disorders

Additional information relating to breastfeeding To be used in conjunction with individual drug entries for specific information and guidance. Oral anticoagulants The coumarin anticoagulants, warfarin…

What factors should be considered when using LMWH to treat venous thromboembolism in patients with high body weight?

Treatment of venous thromboembolism (VTE) in patients with high body weight constitutes a challenge in clinical practice. Adjustments in the dose calculation may be necessary…

Are low molecular weight heparins preferred to unfractionated heparin in people with renal impairment for treatment indications?

Please note this Medicines Q&A was researched and written over 2 years ago. When using this document it is important to consider new information which…

ARCHIVED NPSA Alert - Reducing treatment dose errors with low molecular weight heparins 2010

This page forms part of a resource on medication related patient safety alerts issued  by the National Patient Safety Agency (NPSA) between 2002 and 2012…